Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Jun 2022
Historique:
received: 18 05 2022
revised: 08 06 2022
accepted: 08 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by repetitive and stereotyped behaviors as well as difficulties with social interaction and communication. According to reports for prevalence rates of ASD, approximately 1~2% of children worldwide have been diagnosed with ASD. Although there are a couple of FDA (Food and Drug Administration)-approved drugs for ASD treatment such as aripiprazole and risperidone, they are efficient for alleviating aggression, hyperactivity, and self-injury but not the core symptoms. Serotonin (5-hydroxytryptamine, 5-HT) as a neurotransmitter plays a crucial role in the early neurodevelopmental stage. In particular, 5-HT has been known to regulate a variety of neurobiological processes including neurite outgrowth, dendritic spine morphology, shaping neuronal circuits, synaptic transmission, and synaptic plasticity. Given the roles of serotonergic systems, the 5-HT receptors (5-HTRs) become emerging as potential therapeutic targets in the ASD. In this review, we will focus on the recent development of small molecule modulators of 5-HTRs as therapeutic targets for the ASD treatment.

Identifiants

pubmed: 35742963
pii: ijms23126515
doi: 10.3390/ijms23126515
pmc: PMC9223717
pii:
doi:

Substances chimiques

Receptors, Serotonin 0
Serotonin 333DO1RDJY
Aripiprazole 82VFR53I78
Risperidone L6UH7ZF8HC

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Research Foundation of Korea
ID : NRF-2022R1C1C1006143
Organisme : National Research Foundation of Korea
ID : NRF-2021R1A2C2006244
Organisme : Korea Institute of Science and Technology
ID : 2E31512
Organisme : Korea Institute of Science and Technology
ID : 2E31523

Références

ACS Chem Neurosci. 2015 Jul 15;6(7):1259-70
pubmed: 26011730
Genome Biol. 2012 Jul 31;13(7):247
pubmed: 22849751
J Autism Dev Disord. 2009 Jan;39(1):97-104
pubmed: 18592367
Am J Med Genet. 1999 Oct 15;88(5):472-5
pubmed: 10490701
Dialogues Clin Neurosci. 2012 Sep;14(3):263-79
pubmed: 23226952
Oncogene. 2001 Mar 26;20(13):1661-8
pubmed: 11313914
Neuropharmacology. 2006 Mar;50(4):412-20
pubmed: 16298400
Trends Cogn Sci. 2011 Sep;15(9):409-16
pubmed: 21855394
Behav Brain Res. 2016 Oct 15;313:67-70
pubmed: 27378338
J Clin Med. 2020 Mar 31;9(4):
pubmed: 32244359
PLoS One. 2014 Mar 10;9(3):e91402
pubmed: 24614691
Bioorg Med Chem. 2020 Feb 1;28(3):115262
pubmed: 31882369
J Neuropsychiatry Clin Neurosci. 2012 Spring;24(2):191-7
pubmed: 22772667
ACS Chem Neurosci. 2015 Jul 15;6(7):951-60
pubmed: 25590789
Transl Psychiatry. 2012 Jan 10;2:e66
pubmed: 22832728
Behav Brain Res. 2018 Sep 3;349:8-15
pubmed: 29715539
Behav Brain Res. 2011 May 16;219(1):123-31
pubmed: 21232556
Neuropsychopharmacology. 2004 Jan;29(1):93-100
pubmed: 14571256
Autism Res. 2014 Aug;7(4):459-67
pubmed: 24753316
ACS Chem Neurosci. 2017 May 17;8(5):1019-1025
pubmed: 28076682
Psychopharmacology (Berl). 2012 Sep;223(2):237-45
pubmed: 22549762
Autism Res. 2014 Oct;7(5):555-67
pubmed: 24894823
Neuroscience. 2016 May 3;321:24-41
pubmed: 26577932
Ped Health. 2010 Sep 29;4(4):375-381
pubmed: 21359119
ACS Pharmacol Transl Sci. 2020 Feb 21;3(3):509-523
pubmed: 32566916
Psychol Med. 1999 Jul;29(4):769-86
pubmed: 10473304
Br J Pharmacol. 1997 Feb;120(4 Suppl):134-9; discussion 132-3
pubmed: 9142401
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5469-74
pubmed: 22431635
Brain Res Bull. 2001 Nov 15;56(5):479-85
pubmed: 11750793
J Pharmacol Sci. 2011;116(4):388-91
pubmed: 21778664
PLoS One. 2015 Aug 26;10(8):e0136494
pubmed: 26308619
Cogn Behav Neurol. 2014 Jun;27(2):107-16
pubmed: 24968012
EMBO Mol Med. 2012 Oct;4(10):1043-56
pubmed: 23027611
Molecules. 2021 Jun 02;26(11):
pubmed: 34199418
Behav Brain Res. 2008 Dec 16;195(1):112-9
pubmed: 18191236
Autism Res. 2013 Jun;6(3):149-68
pubmed: 23495208
Cell Mol Life Sci. 2019 Apr;76(7):1275-1297
pubmed: 30570672
J Med Chem. 2021 Sep 23;64(18):13766-13779
pubmed: 34519505
EMBO Mol Med. 2020 May 8;12(5):e10605
pubmed: 32329240
Psychopharmacology (Berl). 2014 Mar;231(6):1191-200
pubmed: 23975037
Genes Brain Behav. 2017 Mar;16(3):342-351
pubmed: 27717169
J Neurochem. 1996 Jan;66(1):47-56
pubmed: 8522988
Neurobiol Learn Mem. 2021 Sep;183:107462
pubmed: 34015444
Neuroreport. 1994 Dec 20;5(18):2553-7
pubmed: 7696602
Exp Neurobiol. 2011 Dec;20(4):159-68
pubmed: 22355260
ACS Chem Neurosci. 2019 Oct 16;10(10):4319-4327
pubmed: 31468969
Brain Res. 1997 Jan 23;746(1-2):207-19
pubmed: 9037500
Psychopharmacology (Berl). 2021 Sep;238(9):2381-2392
pubmed: 34264367
Mol Pharmacol. 2009 Feb;75(2):374-80
pubmed: 18996971
J Med Chem. 2021 Jun 10;64(11):7453-7467
pubmed: 34032427
Arch Gen Psychiatry. 2011 Nov;68(11):1104-12
pubmed: 21727247
ACS Chem Neurosci. 2019 Jul 17;10(7):3241-3248
pubmed: 30645940
J Med Chem. 2018 Aug 23;61(16):7218-7233
pubmed: 30028132
Mol Pharmacol. 1993 Mar;43(3):320-7
pubmed: 7680751
Ir J Psychol Med. 2021 Apr 05;:1-15
pubmed: 33818321
Acta Neuropathol. 2017 Oct;134(4):537-566
pubmed: 28584888
Science. 2006 Jan 6;311(5757):77-80
pubmed: 16400147
Pharmacol Rep. 2010 Jul-Aug;62(4):564-77
pubmed: 20884998
J Neurochem. 2017 Dec;143(6):708-721
pubmed: 28948999
Nat Rev Dis Primers. 2020 Jan 16;6(1):5
pubmed: 31949163
Neuropsychopharmacology. 2009 Jul;34(8):1958-67
pubmed: 19322172
J Biol Chem. 2010 Mar 26;285(13):10016-10029
pubmed: 20093369
Nat Neurosci. 2016 Oct 26;19(11):1408-1417
pubmed: 27786181
J Clin Med Res. 2009 Jun;1(2):72-80
pubmed: 22505971
J Pharmacol Exp Ther. 2012 Aug;342(2):429-40
pubmed: 22570363
Nat Neurosci. 2015 Feb;18(2):199-209
pubmed: 25599223
Behav Brain Res. 2016 Nov 1;314:52-64
pubmed: 27439030
Int J Mol Sci. 2018 Sep 19;19(9):
pubmed: 30235871
Eur J Pharmacol. 2021 Jan 5;890:173635
pubmed: 33065094
Lancet. 2009 Nov 7;374(9701):1627-38
pubmed: 19819542
Neuropsychopharmacology. 2000 Feb;22(2):163-7
pubmed: 10649829
Med Hypotheses. 2010 May;74(5):880-3
pubmed: 20018455
Neuroscience. 2018 Aug 21;386:1-15
pubmed: 29940216
Psychopharmacology (Berl). 2016 Mar;233(6):937-47
pubmed: 26694810
Horm Behav. 2016 Nov;86:71-77
pubmed: 27712925
Mol Pharmacol. 2011 Feb;79(2):318-25
pubmed: 21062995
Ann Neurol. 1997 Oct;42(4):666-9
pubmed: 9382481
Eur J Pharmacol. 2006 Dec 28;553(1-3):109-19
pubmed: 17069795
J Autism Dev Disord. 2007 Nov;37(10):1934-40
pubmed: 17165147
N Engl J Med. 2013 Dec 19;369(25):2406-15
pubmed: 24350950
Front Pharmacol. 2019 Feb 19;10:125
pubmed: 30837883
ACS Chem Neurosci. 2021 Apr 21;12(8):1313-1327
pubmed: 33792287
Biochem Biophys Res Commun. 1993 May 28;193(1):268-76
pubmed: 8389146
J Med Chem. 2017 Nov 22;60(22):9114-9141
pubmed: 29039668
Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):11-26
pubmed: 14965241
Pediatrics. 2020 Jan;145(1):
pubmed: 31843864
Pharmacol Rev. 2021 Jan;73(1):310-520
pubmed: 33370241
Behav Brain Res. 2020 Oct 1;395:112861
pubmed: 32814148
J Neurochem. 1997 Apr;68(4):1372-81
pubmed: 9084407
J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1110-1119
pubmed: 19797985
Dialogues Clin Neurosci. 2012 Sep;14(3):293-305
pubmed: 23226954
Neuroscience. 2014 May 16;267:1-10
pubmed: 24583042
J Child Adolesc Psychopharmacol. 2009 Jun;19(3):265-74
pubmed: 19519261
Ann Neurol. 1999 Mar;45(3):287-95
pubmed: 10072042
Neuropharmacology. 2011 Sep;61(4):632-7
pubmed: 21619890
Front Cell Neurosci. 2014 Aug 27;8:250
pubmed: 25221471
Br J Pharmacol. 2000 May;130(1):23-6
pubmed: 10780993
Bioorg Med Chem Lett. 2018 Aug 1;28(14):2418-2421
pubmed: 29910079
Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):1-10
pubmed: 14965240
Behav Brain Res. 2015 Jan 15;277:3-13
pubmed: 24859172
Dev Neurosci. 1992;14(1):1-10
pubmed: 1350976
J Med Chem. 2003 Mar 27;46(7):1273-6
pubmed: 12646038
Pharmacol Biochem Behav. 2021 Jan;200:173076
pubmed: 33220385
J Med Chem. 2015 Oct 22;58(20):7901-12
pubmed: 26099069
J Biol Chem. 2007 Feb 23;282(8):5496-505
pubmed: 17189269
Neurosci Lett. 2010 Feb 5;470(1):55-9
pubmed: 20036713
Prog Neurobiol. 2017 Apr;151:35-56
pubmed: 27013076
Psychopharmacology (Berl). 2014 Apr;231(8):1503-15
pubmed: 24057815
J Biol Chem. 1948 Dec;176(3):1243-51
pubmed: 18100415
Genes Brain Behav. 2003 Oct;2(5):255-67
pubmed: 14606691
Psychopharmacology (Berl). 2012 Apr;220(4):687-96
pubmed: 21989804

Auteurs

Ansoo Lee (A)

Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea.

Hyunah Choo (H)

Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea.

Byungsun Jeon (B)

Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH